AI-Assisted Technology Platform to Be Used in Hunt for Most Effective COVID-19 Treatments
By HospiMedica International staff writers Posted on 16 Jul 2020 |
Image: AI-Assisted Technology Platform to Be Used in Hunt for Most Effective COVID-19 Treatments (Photo courtesy of Doctor Evidence)
New tools for automated network meta-analysis are now being used in the hunt for the most effective treatments for COVID-19.
Doctor Evidence (DRE Santa Monica, CA, USA), a Software-as-a-Service (SaaS) company in the AI-enabled health technology marketplace, is offering its DOC Analytics platform for real time aggregation of all the clinical trial data that is continuously emerging.
Currently, about 1,798 COVID-19 treatment trials are underway across the world and preliminary results and data from high-profile trials are now available, including for Remdesivir, Dexamethasone, and Hydroxychloroquine. DRE is using its first-in-industry DOC Analytics platform to generate real-time network meta-analysis for researchers to produce quantitative analysis for any therapeutic question in the global landscape. This approach will inform decision-makers with regard to real-time updates from clinical trials for quantitative comparison, analysis, and reporting on relevant outcomes.
This novel quantitative analytic approach leverages DRE’s open DOC Search platform for COVID-19, which makes available annotated set of literature from CORD19, the open research dataset made available by the Allen Institute in response to the White House Task Force call to action in late March. DOC Search provides the foundation of medical conceptual organization to identify which key concepts are being reported across literature and trials.
“We are breaking new ground in AI-assisted technology at a critical time for healthcare,” said Bob Battista, MBA, FRCPH, FRCP Edin., Co-founder and Chief Executive Officer of DRE. “Our industry-first automated network meta-analysis technology and AI-enabled search engine are being utilized for rapid assessment of drug candidates for COVID-19. DOC Search and Analytics are being used as a foundational tool by top 10 industry ranked global pharmaceutical/life science companies that are DRE clients.”
Related Links:
Doctor Evidence
Doctor Evidence (DRE Santa Monica, CA, USA), a Software-as-a-Service (SaaS) company in the AI-enabled health technology marketplace, is offering its DOC Analytics platform for real time aggregation of all the clinical trial data that is continuously emerging.
Currently, about 1,798 COVID-19 treatment trials are underway across the world and preliminary results and data from high-profile trials are now available, including for Remdesivir, Dexamethasone, and Hydroxychloroquine. DRE is using its first-in-industry DOC Analytics platform to generate real-time network meta-analysis for researchers to produce quantitative analysis for any therapeutic question in the global landscape. This approach will inform decision-makers with regard to real-time updates from clinical trials for quantitative comparison, analysis, and reporting on relevant outcomes.
This novel quantitative analytic approach leverages DRE’s open DOC Search platform for COVID-19, which makes available annotated set of literature from CORD19, the open research dataset made available by the Allen Institute in response to the White House Task Force call to action in late March. DOC Search provides the foundation of medical conceptual organization to identify which key concepts are being reported across literature and trials.
“We are breaking new ground in AI-assisted technology at a critical time for healthcare,” said Bob Battista, MBA, FRCPH, FRCP Edin., Co-founder and Chief Executive Officer of DRE. “Our industry-first automated network meta-analysis technology and AI-enabled search engine are being utilized for rapid assessment of drug candidates for COVID-19. DOC Search and Analytics are being used as a foundational tool by top 10 industry ranked global pharmaceutical/life science companies that are DRE clients.”
Related Links:
Doctor Evidence
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans